eIF2B (eukaryotic initiation factor 2B) is a GEF (guanine nucleotide-exchange factor) that plays, with its substrate eIF2, a key regulatory role in the translation initiation phase of protein synthesis. The importance of correct control of eIF2 and eIF2B for normal physiology is underlined by the recent involvement of the five genes that encode the five eIF2B subunits in a severe autosomal recessive neurodegenerative disease, described in young children as CACH (childhood ataxia with central nervous system hypomyelination)/VWM (leukoencephalopathy with vanishing white matter) syndrome. The syndrome is characterized by episodes of rapid deterioration during febrile illnesses or following head trauma and symmetrical demyelination of the brain white matter with cavitation aspects, leading to a progressive vanishing of the white matter replaced by CSF (cerebrospinal fluid). However, a wide clinical spectrum has been observed in the 148 patients presently reported, from congenital forms with rapid death to adult-onset forms with slow mental decline and progressive motor dysfunction, sometimes associated with congenital eye abnormalities or ovariodysgenesis. So far, 77 different mutations in each of the five EIF2B genes (EIF2B1-5), encoding subunits eIF2Bα-ε, have been found, with two-thirds affecting the eIF2Bε subunit. The correlation found between the level of GEF activity of eIF2B in the mutated white blood cells and the age at disease onset suggests a direct role of the abnormal translation control in the pathophysiology of the disease.
Introduction
Translation initiation in mammalian cells is a complex process that involves a set of proteins, the eukaryotic initiation factors (eIF). eIF2B, owing to its GEF (guanine nucleotideexchange factor) activity, catalyses the recycling of eIF2 between consecutive rounds of peptide-chain initiation (Figure 1 ). This recycling step is a key regulatory point in the initiation of translation, and is regulated under a variety of physiological conditions. The recent involvement of the five genes that encode the five eIF2B subunits in a severe neurodegenerative disease, described in young children as CACH [childhood ataxia with CNS (central nervous system) hypomyelination]/VWM (leukoencephalopathy with vanishing white matter) syndrome has emphasized the key physiological role of this factor and has underlined the susceptibility of the brain white matter to abnormal regulation of protein synthesis during development and in response to cellular stress.
Key words: childhood ataxia with central nervous system hypomyelination/leukoencephalopathy with vanishing white matter syndrome (CACH/VWM syndrome), eukaryotic initiation factor 2B (eIF2B), guanine nucleotide-exchange factor (GEF), leukodystrophy, translation, translation regulation. Abbreviations used: ATF4, activating transcription factor 4; CACH, childhood ataxia with central nervous system hypomyelination; CNS, central nervous system; eIF, eukaryotic initiation factor; GADD, growth arrest and DNA-damage-inducible protein; GCN, general control nonderepressible; GEF, guanine nucleotide-exchange factor; GSK3, glycogen synthase kinase 3; HEK-293, human embryonic kidney 293; HRI, haem-regulated inhibitor; Met-tRNAi Met , aminoacylated initiator methionyl-tRNA; MRI, magnetic resonance imaging; PERK, RNA-activated kinaselike endoplasmic reticulum protein kinase; PKR, double-stranded RNA-activated kinase; uORF, upstream open reading frame; UTR, untranslated region; VWM, leukoencephalopathy with vanishing white matter. 1 To whom correspondence should be addressed (email odile.boespflug@inserm.uclermont1.fr).
A mysterious disease: CACH/VWM syndrome
In early 1990s, several reports described in young children a new neurological condition called MCD ('myelinopathia centralis diffusa') by Hanefeld et al. [1] in 1993 or CACH by Schiffmann et al. [1a] in 1994. This new disease appeared to be inherited as an autosomal recessive trait. After an initial usually normal development, patients between 2-and 5-years-old experience a neurological deterioration characterized by progressive gait difficulties with a relatively mild cognitive impairment. Additional episodes of acute deterioration after febrile infections or minor head trauma often occurred with subsequent partial recovery, leading to death usually after 2-5 years of disease evolution. MRI (magnetic resonance imaging) reveals a diagnosis pattern with symmetric and diffuse involvement of the cerebral hemispheres in which increasing areas of abnormal white matter show a CSF (cerebrospinal fluid)-like signal intensity (Figure 2) . This MRI pattern explains the term of VWM subsequently coined by van der Knaap in 1997 [2] for this entity. Neuropathological analysis confirms the extensive loss of brain myelin with a relative sparing of axons. Diffuse vacuolation results in an appearance of the white matter from spongiform to cavitated [1a,3-5] . Preservation of oligodendrocytes [4] , the CNS myelinating cells, with abundant 'foamy' cytoplasm contrasting with a scarcity of astrocytes is considered to be the most specific neuropathologic hallmark of the disease [5] .
eIF2B is involved in CACH/VWM
Using a positioning cloning strategy in the 3q27 region, mutations in the EIF2B5 gene were first found in patients with The GEF activity of eIF2B allows conversion of eIF2 from an inactive GDP-bound form into an active eIF2-GTP complex. Activation of eIF2 is necessary for eIF2 binding to Met-tRNA, forming a 43 S initiation complex consisting of eIF3, eIF5 and the 40 S ribosomal subunit. a CACH/VWM phenotype [6] . Subsequently, in patients without EIF2B5 mutations, by gene homology functions, the four genes encoding the four other subunits of the eIF2B heteropentameric complex were identified: EIF2B1 (12q24) for the α subunit, EIF2B2 (14q24) for the β one, EIF2B3 (1p36.23) for the δ one, and EIF2B4 (2p23) for the γ one [6, 7] .
The wide spectrum of eIF2B-related diseases
The use of MRI or neuropathology-based criteria to select patients with undetermined leukodystrophies for EIF2B genes analysis demonstrated the wide clinical spectrum of patients with eIF2B mutations, from congenital forms with rapid death to adult-onset forms with slow neurological progression leading to the concept of eIF2B-related disorders [8] . A total of 148 eIF2B-mutated patients have been reported (Table 1) . Clinical symptoms and diseases severity are correlated with age at disease onset [8] . Using survival curve analysis, three groups of severity were described. The group 2 with an onset between 2-and 5-years-old corresponds to the classical forms described initially as CACH/VWM and represents the largest group of eIF2B-mutated patients (41%). The most severe group (group 1) with a disease onset before 2-years-old is less frequently observed (18% of the eIF2B-mutated patients). It includes the so-called 'Cree leukoencephalopathy', described in a consanguineous population of Cree and Chipewayan Indians with an age of onset at approx. 3 months of age and a rapid decline leading to death sometimes in few hours [13] . In the milder group (group 3), onset occurs after 5 years of age with slow or absent neurological deterioration and long survival [8] . This juvenileadult form was found in 22% of eIF2B-mutated patients; however, this entity is not yet well recognized in adult patients with undetermined leukodystrophies. In this lateonset form, association with an ovarian failure, defined as ovarioleukodystrophies [14] , can help to recognize eIF2B-related leukodystrophies. A correlation exists between age of onset of neurological deterioration and severity of ovarian failure. Congenital forms (group 0) have been reported recently and are probably also underestimated (representing only 2%). Intrauterine growth retardation and oligohydramnios are associated with multiorgan involvement including dysmorphic features, joint contractures, ovarian dysgenesis, hypoplasia of kidneys, liver and pancreas dysfunctions and cataracts [10] .
The wide spectrum of EIF2B mutations
Mutations in each of the five EIF2B genes have been found in more than 95% of individuals with clinical and MRI characteristics of CACH/VWM using sequence analysis or mutation scanning [6] [7] [8] [9] 12] . To date, 77 different mutations have been described in 148 patients ( Table 1 ). The vast majority are missense mutations (90%). Frameshifts and premature terminations are never observed in a homozygous state, presumably because absence of active eIF2B complexes is incompatible with survival, as observed in yeast.
The two mutated alleles always affected the same subunit: 63% in the ε subunit, 19% in β, 12% in δ, and, less rarely, the γ (4%) and α (2%) subunits. No hotspot mutations in specific domains of the different subunits were found (Figure 3) . However, the R113H mutation is found in 60% of eIF2Bε-mutated patients in a compound heterozygous (68%) or homozygous state (32%), and the E213G substitution is found in 64% of eIF2Bβ-mutated patients, in a homozygous state for 55% of them (Table 1) . Therefore detection of only these two R113H-eIF2Bε and E213G-eIF2Bβ mutations allows diagnosis of 51% of eIF2B-mutated patients.
Genotype-phenotype correlation in eIF2B-related disease
Affected patients within the same family exhibit similar disease severity, although differences are wider in the mildest group. This suggests a certain genotype-phenotype correlation [8] .
eIF2B regulatory and catalytic activities are optimal when the five subunits are present, but the mutual sequence similarities between certain subunits enable the formation of two distinct subcomplexes: the catalytic complex (γ and ε subunits), and the regulatory complex (α, β and δ subunits) [15, 16] . No correlation was observed clearly between the affected subunit and the degree of disease severity. The most severe homozygote mutations (phenotypes 0 and 1) have been described in both complexes in the ε and δ subunits (Figure 3 ) [10, 13] . The wider range of disease severity observed in eIF2Bε mutations could be explained by the higher frequency of EIF2B5 mutations.
The largest subunit of eIF2B, ε, contains crucial domains in its C-and N-terminal conserved domains involved in catalytic and regulation activities. The C-terminal domain contains the catalytic GEF domain (residues 518-712) [17, 19] and binds eIF2Bβ [18] . The N-terminal region of eIF2Bε binds to subunits α and δ and acts as an activation domain that responds to eIF2B complex formation [19] . No correlation was observed between the position of the mutations in the eIF2Bε domains and the disease severity: the homozygous R195H and R113H mutations affected the same C-terminal domain of eIF2Bε.
However, correlation between certain mutations at the homozygous state and the age of disease onset and severity exists. One particularly severe form of CACH/VWM [20] has been found to result from a homozygous missense mutation in EIF2B5, V309L, never reported in any of the less severe cases of CACH/VWM. A further severe mutation, R195H, has been found in a homozygous state in cases of Cree leukoencephalopathy [13] . When this R195H mutation is compounded with the R113H one, it seems to have a protective effect from the most severe phenotype (Table 1) . Both substituted amino acid residues are highly conserved in mouse, rat, Drosophila and yeast eIF2Bε, and could partially explain the severe phenotype observed. In contrast, patients with the homozygous mutations, R113H in eIF2Bε and E213G in eIF2Bβ, express the mildest forms [8] . Arg 113 is not conserved among species. In fact, the mouse and rat protein has a histidine residue at the equivalent position. This could explain why, in humans, the R113H mutation is responsible for a milder phenotype. However, this residue is highly conserved in vertebrates (including pig, chicken and zebrafish) other than rats and mice [8] . In addition, in the eIF2Bβ subunit, despite the fact that the glutamate residue at position 213 is highly conserved among species, its homozygous replacement with glycine leads to mild forms identical with the R113H homozygote mutations (Table 1) .
Decreased GEF activity in eIF2B-mutated cells
The primary role of eIF2B in translation initiation is to activate the eIF2 factor. eIF2 is a GTP-binding protein, which can bind either GDP or GTP, is regulated by GTP/GDP binding and is active only in a GTP-bound form. The eIF2-GTP binds Met-tRNA i Met (aminoacylated initiator methionyl-tRNA), forming a ternary complex, which is then loaded on the small ribosomal subunit before each translation event (for a review, see [21] ). Thus regeneration of active eIF2 is essential for continued protein synthesis. eIF2 consists of three subunits: the α subunit participates in the regulation of the translation initiation step through its phosphorylation at Ser 51 (human), the β subunit can bind eIF5 and eIF2B, and the γ subunit possesses the binding site for MettRNA i Met (for a review, see [22] ). eIF2B promotes release of GDP from eIF2 by acting as a GDP-dissociation stimulator protein and permits the exchange with GTP, allowing the activation of eIF2. Therefore eIF2B modulates the rate of GDP/GTP exchange, which is a key regulatory step for translation, both for overall rates of protein synthesis and for translation of certain specific mRNAs [22] .
In order to evaluate the functional consequences of eIF2B mutations, several studies have analysed the integrity and 
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function of the eIF2B complex in different cellular models: transformed lymphocytes of eIF2B-related patients [23] , mutated yeast [24] and transformed HEK-293 (human embryonic kidney 293) cells carrying human eIF2B mutations [25] . These data show that all the CACH/VWM mutations tested cause partial loss of function of human and yeast eIF2B. The magnitude of the effect differs between mutations [24, 25] . When we measured the GEF activity of eIF2B in transformed lymphocytes from 30 affected patients carrying various mutations in eIF2B compared with ten unaffected heterozygotes and 22 controls without eIF2B mutations, a significant decrease of 20-70% was observed in all mutated cells. The severity of this decrement of GEF activity correlated with age at onset of the disease, particularly in the youngest, more severe, groups [23] . The magnitude and basis of the decreased eIF2B activity differs between mutations (inability to form holocomplexes, reduced stability of the complex, failure of eIF2B to bind eIF2 correctly), prompting the possibility that the variable phenotype of the condition may reflect the distinct ways in which different mutations affect the eIF2B complex [24, 25] .
Abnormal stress response in eIF2B-mutated cells eIF2B activity (and therefore ternary complex availability) is subject to tight regulation that links the global translation rate to the current physiological requirements of the cell. GEF activity of eIF2B is subjected to direct control through its own phosphorylation. eIF2Bε contains multiple phosphorylation sites which are phosphorylated by different protein kinases: GSK3 (glycogen synthase kinase 3), CK1 and CK2 [26] . Phosphorylation of the more N-terminal site (Ser 535 in human) by GSK3 decreases the activity of eIF2B [27] . Another important and well-characterized mechanism that regulates the rate of translation initiation is based on phosphorylation of Ser 51 of the α subunit of eIF2. In response to various cellular stresses, four different kinases [HRI (haem-regulated inhibitor), PKR (double-stranded RNA-activated kinase), GCN2 (general control non-derepressible 2) and PERK (PKR-like endoplasmic reticulum protein kinase)] can be activated in mammalian cells, leading to phosphorylation of eIF2α (for a review, see [22, 28] ). This eIF2α phosphorylation The different eIF2B mutations reported are observed in the catalytic (γ and ε subunits) and regulatory (α, β and δ subunits) subcomplexes of the protein, without hotspot mutations. The majority of the mutations are observed in the ε subunit, affecting the C-terminal catalytic domain as well as the N-terminal regulatory domain. No correlation exists between the clinical severity score (in grey: the neonatal congenital forms, group 0; framed: the infantile forms, group 1 with disease onset <2 years old; underlined: the classical childhood forms, group 2 with disease onset at between 2-and 5-years old; in italic: the juvenile-adult forms, group 3 with disease onset >5 years old; ?: clinical features not described) of the homozygous mutations (in bold with *) and the position of the mutation. The number in parentheses corresponds to the number of mutated alleles reported to date.
converts eIF2 from a substrate into a competitive inhibitor of eIF2B. The increased affinity of eIF2B for eIF2α(P) results in a tight binding between the two molecules and, in the effective sequestration of eIF2B, into an inactive complex. This leads to a rapid reduction in the rate of protein synthesis owing to inhibition of eIF2B activity [29] . Under such conditions of eIF2 dysfunction and translation inhibition, some mRNAs are still efficiently translated due to specific regulatory sequences [uORFs (upstream open reading frames)] within their 5 -UTR (untranslated region). Examples are the transcription factors of the yeast GCN4 and its mammalian homologue ATF4 (activating transcription factor 4) [30, 31] . Once the transcription factors are present in sufficient amounts, they lead to transcription activation of numerous downstream genes, including CHOP (CCAAT/enhancer-binding protein homologous protein) [or GADD153 (growth arrest and DNA-damage-inducible protein 153)] and GADD34.
The reduction in eIF2B function by CACH/VWM mutations alters these translationally controlled stress responses. Indeed, eIF2B dysfunction in yeast leads to the translational activation of GCN4, in the absence of GCN2 activity [24] . Similarly, in HEK-293 cells carrying human eIF2B mutations, decrease in eIF2B activity leads to up-regulation of the translation of ATF4 [25] . More recently, Kantor et al. [32] used primary fibroblasts from CACH/VWM patients to analyse global protein synthesis and ATF4 induction in response to stress in the endoplasmic reticulum. They showed that, although the cells expressing mutant EIF2B genes respond normally to stress conditions by reduced global translation rates, they exhibited significantly greater increases in ATF4 induction compared with controls, despite equal levels of stress and activity of the upstream eIF2α kinase. Abnormal increases of ATF4 can subsequently affect the expression of many other genes [33, 34] . This heightened stress response in cells that suffer from a minor loss of basal eIF2B activity can explain the acute deterioration frequently observed after febrile infections or minor head trauma in CACH/VWM patients.
Brain white matter sensitivity to eIF2B mutations
Although eIF2B is a ubiquitous protein, its mutation affects essentially the white matter of the brain. However, EIF2B mutations seem to disturb cellular events that also occur also in non-CNS tissue during the development: eyes, kidney, liver, pancreas and ovaries. The correlation observed between the age at onset of the neurological deterioration, the number of organs involved and the severity of the ovarian failure suggests a common pathophysiological mechanism. Ovarian dysgenesis and premature ovarian failure result from an alteration in the maturation of the follicles which undergo successive programmed cell death during development. In the brain of patients with CACH/VWM syndrome, an increase in the number of mature oligodendrocytes that have foamy aspects but lack apoptotic features has been reported frequently [4, 5, 13, 36] . In addition, astrocyte abnormalities have been reported in early-onset VWM disease [13, 35] . More recently, cell cultures established from the brain of an individual carrying an eIF2Bε mutation confirmed than normally appearing oligodendrocytes were generated, whereas induction of astrocytes was severely compromised. Similarly, RNAi (RNA interference) targeting of EIF2B5 compromised the induction of GFAP + (glial fibrillary acidic protein) cells from normal human glial progenitors [36] . This raises the possibility that a deficiency in astrocyte maturation may contribute to the abnormal white matter observed in patients with eIF2B mutations even at a pre-symptomatic stage. In addition, myelin biogenesis is a highly regulated process that requires co-ordination of numerous events which require intensive use of the ER. White matter is extremely sensitive to injury by oxidative stress, brain trauma and hypoxia/ ischaemia. Local ischaemia in the brain induces inhibition of eIF2B activity by eIF2α phosphorylation [37] and the eIF2 kinase activated upon hypoxia is PERK [38] . Therefore the white matter susceptibility to eIF2B mutations could result from both an abnormal glial maturation and the sensitivity of glial cells to eIF2B dysfunction during life. When EIF2B mutations induce a minor loss of basal eIF2B activity, the heightened stress response that is observed can be modulated by environmental factors, which could explain the larger intrafamilial variability of disease evolution observed in the mildest group.
Conclusion
eIF2B-related disorders represent the first neurodegenerative disorders owing to an abnormal translation regulation, induced by a decrease in the GEF activity of eIF2B. Consequences affect the maturation of glial cells as well as other non-CNS cells during the development. In the postnatal life, the heightened stress response in eIF2B-mutated cells is responsible for the progressive neurological degradation, precipitated by acute phases under stress conditions. Diagnosis-based MRI helps to select patients that are eligible for eIF2B analysis. No therapeutics presently exist. Compounds that are able to restore a normal GEF activity of eIF2B would probably prevent the progression of the disease, particularly under stress conditions. A description of CACH/VWM patients with a dominant transmission of the disease who do not have mutations in eIF2B and have a normal GEF activity [39] suggests that other genes that are involved in the endoplasmic reticulum stress cascade could be involved in this devastating group of neurodegenerative disorders.
